Santhera Secures CHF 20 Million Growth Funding to Accelerate Global AGAMREE® Rollout

Core Viewpoint - Santhera Pharmaceuticals has secured approximately CHF 20 million in additional funding to support the global rollout of AGAMREE® (vamorolone) for the treatment of Duchenne muscular dystrophy (DMD), driven by increased demand and inventory needs [2][3][8] Financing Agreements - Santhera has entered into financing agreements with R-Bridge and Highbridge Capital Management, securing USD 13 million through royalty monetization and CHF 10 million via an upsized convertible bond [4][5][7] - The royalty monetization with R-Bridge allows them to receive 25% of net royalties from AGAMREE sales in North America and China, with a payment of USD 13 million to Santhera upon closing [5][6] - Highbridge's additional CHF 10 million will be provided through a new convertible note, extending the maturity of an existing bond and offering increased flexibility [7] Market Demand and Performance - AGAMREE has treated over 1000 patients globally, with strong sales performance reported in the U.S. at USD 49.4 million for the first half of 2025, driven by physician adoption [2][5] - Demand for AGAMREE is expected to increase in China following its launch into the private-pay market, with expectations for growth in 2025 and 2026 [2][5] Strategic Goals - The additional funding will enable Santhera to accelerate product launches, build inventory, and aim for cash flow break-even by 2026 [5][8] - The company continues to maintain partnerships with high-quality investors to support its growth trajectory [5]